Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Trojano

Showing results (271-280 of 342) with videos related to

Pageof 35
Sort By:
Neurology|November 24, 2025
Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying TreatmentsErmelinda De Meo, Ilaria Addazio, Emilio Portaccio, et al.
Neurology|September 22, 2025
Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple SclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 2, 2026
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosisNail Benallegue, Fabien Rollot, Pietro Iaffaldano, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|September 20, 2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterDamiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|September 4, 2024
Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Journal of Neurology|May 28, 2024
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Multiple Sclerosis and Related Disorders|June 8, 2022
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple SclerosisMarta Ponzano, Irene Schiavetti, Francesca Bovis, et al.
Pageof 35

Showing results (271-280 of 342) with videos related to

Sort By:
Pageof 35
Neurology|November 24, 2025
Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying TreatmentsErmelinda De Meo, Ilaria Addazio, Emilio Portaccio, et al.
Neurology|September 22, 2025
Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple SclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 2, 2026
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosisNail Benallegue, Fabien Rollot, Pietro Iaffaldano, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|September 20, 2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterDamiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|September 4, 2024
Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Journal of Neurology|May 28, 2024
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Multiple Sclerosis and Related Disorders|June 8, 2022
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple SclerosisMarta Ponzano, Irene Schiavetti, Francesca Bovis, et al.
Pageof 35